Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

Merck & Co., Inc. (MRK) Stock Price, News & Analysis

Merck & Co., Inc. logo
$145.25 -1.99 (-1.35%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$145.40 +0.15 (+0.10%)
As of 10/23/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Merck & Co., Inc. Stock (NYSE:MRK)

Advanced

Key Stats

Today's Range
$143.41
▼
$145.44
50-Day Range
$135.34
▼
$156.54
52-Week Range
$82.01
▼
$156.92
Volume
8.38 million shs
Average Volume
9.66 million shs
Market Capitalization
$358.35 billion
P/E Ratio
116.20
Dividend Yield
2.34%
Price Target
$151.92
Consensus Rating
Moderate Buy

Company Overview

Merck & Co., Inc. is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes. Its portfolio also includes products such as Bridion, which reverses certain effects of muscle-relaxing medicines used during surgery. Through Merck Animal Health, the company provides vaccines, pharmaceutical products and technology-enabled solutions for livestock, companion animals and aquaculture.

The company traces its roots to the U.S. operations established by the Merck family in 1891 and operates independently from Germany-based Merck KGaA, which uses the name EMD in the United States and Canada. Merck & Co. has research, manufacturing and commercial operations across North America, Europe, Asia-Pacific, Latin America, Africa and other international markets. Robert M. Davis serves as the company’s chairman and chief executive officer.

AI Generated. May Contain Errors.

Merck & Co., Inc. Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

MRK MarketRank™: 
4.60021464985 of 5 stars

Merck & Co., Inc. scored higher than 92% of companies evaluated by MarketBeat, and ranked 28th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Merck & Co., Inc. has received a consensus rating of Moderate Buy. The company's average rating score is 2.59, and is based on no strong buy ratings, 17 buy ratings, 9 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Merck & Co., Inc. is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Merck & Co., Inc. has been the subject of 23 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Merck & Co., Inc.'s stock forecast and price target.
  • Earnings Growth

    Earnings for Merck & Co., Inc. are expected to grow by 250.76% in the coming year, from $2.64 to $9.26 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Merck & Co., Inc. is 116.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.38.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Merck & Co., Inc. is 116.20, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.05.

  • Price to Earnings Growth Ratio

    Merck & Co., Inc. has a PEG Ratio of 6.74. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Merck & Co., Inc. has a P/B Ratio of 6.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Merck & Co., Inc.'s valuation and earnings.
  • Percentage of Shares Shorted

    1.15% of the float of Merck & Co., Inc. has been sold short.
  • Short Interest Ratio / Days to Cover

    Merck & Co., Inc. has a short interest ratio ("days to cover") of 2.53, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Merck & Co., Inc. has recently decreased by 17.89%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Merck & Co., Inc. pays a meaningful dividend of 2.34%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Merck & Co., Inc. has been increasing its dividend for 14 years.

  • Dividend Coverage

    The dividend payout ratio of Merck & Co., Inc. is 272.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 36.72% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.

  • Read more about Merck & Co., Inc.'s dividend.
  • News Sentiment

    Merck & Co., Inc. has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 77 news articles for Merck & Co., Inc. this week, compared to 9 articles on an average week.
  • Search Interest

    Only 49 people have searched for MRK on MarketBeat in the last 30 days. This is a decrease of -2% compared to the previous 30 days.
  • MarketBeat Follows

    40 people have added Merck & Co., Inc. to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Merck & Co., Inc. insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,977,783.00 in company stock.

  • Percentage Held by Insiders

    0.17% of the stock of Merck & Co., Inc. is held by insiders.

  • Percentage Held by Institutions

    76.07% of the stock of Merck & Co., Inc. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Merck & Co., Inc.'s insider trading history.
Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRK Stock News Headlines

He turned $12K into $1.65M without touching Apple or Tesla
Tim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading Apple, Tesla, or Bitcoin. He targets overlooked small-cap stocks that can move fast: $1.50 to $98.40 in a week, $6 to $34 in hours, or 49 cents to $10 in days. Now he is sharing the exact setup he watches for before these moves happen.tc pixel
FY2026 Earnings Estimate for MRK Issued By Erste Group Bank
3 Dividend Stocks That Could Pay You No Matter Who Wins the Midterms
3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach (MRK)
Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.
Eli Lilly, Moderna, Guardant Health and Illumina Ride AI That Reads the Body
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning (MRK)
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.
Office desk with dual computer monitors showing stock charts, printed financial reports, a calculator, and pen near city skyline windows.
3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note (MRK)
With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.
Laboratory workbench with chromatography instrument, pipettes, sample vials, and a notebook, with a production line visible beyond the glass wall.
3 Healthcare Dividend Stocks Offering More Than Just Income (MRK)
AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.
See More Headlines

MRK Stock Analysis - Frequently Asked Questions

Merck & Co., Inc.'s stock was trading at $105.20 at the start of the year. Since then, MRK shares have increased by 38.1% and is now trading at $145.2480.

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. The business's quarterly revenue was up 5.1% on a year-over-year basis.
Read the conference call transcript
.

Merck & Co., Inc.'s Board of Directors initiated a stock buyback program on Tuesday, January 28th 2025, which permits the company to buy back $10,000,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 4.1% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's board believes its stock is undervalued.

Top institutional investors of Merck & Co., Inc. include Robeco Institutional Asset Management B.V. (0.09%), Assenagon Asset Management S.A. (0.06%), Mn Services Vermogensbeheer B.V. (0.03%) and Cacti Asset Management LLC (0.03%). Insiders that own company stock include Robert M Davis, Richard R Deluca, Dean Y Li, Caroline Litchfield, Jennifer Zachary, Chirfi Guindo, David Michael Williams, Steven Mizell, Johannes Jacobus Oosthuizen, Joseph Romanelli, David R Maraldo, Dalton E Smart III, Cristal N Downing and Inge G Thulin.
View institutional ownership trends
.

Shares of MRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Merck & Co., Inc. investors own include Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Verizon Communications (VZ), Chevron (CVX) and Intel (INTC).

Company Calendar

Last Earnings
8/04/2026
Record date for 10/7 Dividend
9/15/2026
Ex-Dividend for 10/7 Dividend
9/15/2026
Dividend Payable
10/07/2026
Today
10/25/2026
Investor update
10/26/2026
Next Earnings (Estimated)
10/29/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:MRK
CIK
310158
Employees
75,000
Year Founded
1891

Price Target and Rating

High Price Target
$180.00
Low Price Target
$92.00
Potential Upside/Downside
+4.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.59
Research Coverage
27 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.25
Trailing P/E Ratio
116.20
Forward P/E Ratio
55.02
P/E Growth
6.74
Net Income
$18.25 billion
Net Margins
4.77%
Pretax Margin
8.94%
Return on Equity
16.73%
Return on Assets
6.13%

Debt

Debt-to-Equity Ratio
1.22
Current Ratio
1.32
Quick Ratio
1.10

Sales & Book Value

Annual Sales
$65.01 billion
Price / Sales
5.51
Cash Flow
$11.42 per share
Price / Cash Flow
12.72
Book Value
$21.22 per share
Price / Book
6.84

Miscellaneous

Outstanding Shares
2,467,170,000
Free Float
2,462,978,000
Market Cap
$358.35 billion
Optionable
Optionable
Beta
0.21

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NYSE:MRK) was last updated on 10/23/2026 by MarketBeat.com Staff.
From Our Partners